Invasive Candidiasis Species Distribution and Trends, United States, 2009–2017
2020/08/04 by Emily E Ricotta, Emily Ricotta, Yi Ling Lai +10 · 27 citations
Medicine · Immunology and Microbiology · #Antifungal resistance and susceptibility #Parasitic Diseases Research and Treatment #Parasites and Host Interactions
paper · pdf · doi:10.1093/infdis/jiaa502
Abstract
BACKGROUND: Invasive candidiasis (IC) is a growing concern among US healthcare facilities. A large-scale study evaluating incidence and trends of IC in the United States by species and body site is needed to understand the distribution of infection. METHODS: An electronic medical record database was used to calculate incidence and trends of IC in the United States by species and infection site from 2009 through 2017. Hospital incidence was calculated using total unique inpatient hospitalizations in hospitals reporting at least 1 Candida case as the denominator. IC incidence trends were assessed using generalized estimating equations with exchangeable correlation structure to fit Poisson regression models, controlling for changes in hospital characteristics and case mix over time. RESULTS: Candida albicans remains the leading cause of IC in the United States, followed by Candida glabrata. The overall incidence of IC was 90/100 000 patients, which did not change significantly over time. There were no changes in incidence among C. albicans, C. glabrata, C. parapsilosis, or C. tropicalis; the incidence of other Candida spp. as a whole increased 7.2% annually. While there was no change in candidemia 2009-2017, abdominal and nonabdominal sterile site IC increased significantly. CONCLUSIONS: Nonbloodstream IC is increasing in the United States. Understanding the epidemiology of IC should facilitate improved management of infected patients.
Cited by
- Trends in Candidemia Over the Last 14 Years: A Comparative Analysis of Candida parapsilosis and Candida albicans
- The Upcoming Antifungal Drugs in Clinical Development for the Treatment of Invasive Candidiasis
- Opportunist Coinfections by Nontuberculous Mycobacteria and Fungi in Immunocompromised Patients. [europepmc]
- Isavuconazole: Mechanism of Action, Clinical Efficacy, and Resistance. [europepmc]
- Increased incidence of candidemia in a tertiary care hospital with the COVID-19 pandemic. [europepmc]
- Trends in Pediatric Candidemia: Epidemiology, Anti-Fungal Susceptibility, and Patient Characteristics in a Children's Hospital. [europepmc]
- Epidemiology, species distribution, and outcome of nosocomial Candida spp. bloodstream infection in Shanghai: an 11-year retrospective analysis in a tertiary care hospital. [europepmc]
- Molecular Diagnosis of Yeast Infections. [europepmc]
- Synergistic Activity of New Diclofenac and Essential Oils Combinations against Different Candida spp. [europepmc]
- Interplay between Candida albicans and Lactic Acid Bacteria in the Gastrointestinal Tract: Impact on Colonization Resistance, Microbial Carriage, Opportunistic Infection, and Host Immunity. [europepmc]
- Epidemiology of Candidemia in Kuwait: A Nationwide, Population-Based Study. [europepmc]
- The interplay between gut bacteria and the yeast Candida albicans . [europepmc]
- Repurposing pantoprazole and haloperidol as efflux pump inhibitors in azole resistant clinical Candida albicans and non-albicans isolates. [europepmc]
- Long-term antibiotic exposure promotes mortality after systemic fungal infection by driving lymphocyte dysfunction and systemic escape of commensal bacteria. [europepmc]
- Friendly fungi: symbiosis with commensal Candida albicans. [europepmc]
- Emerging and re-emerging fungal threats in Africa. [europepmc]
- Interactions between Candida albicans and the resident microbiota. [europepmc]
- Hesperetin-Between the Ability to Diminish Mono- and Polymicrobial Biofilms and Toxicity. [europepmc]
- The Candida glabrata Parent Strain Trap: How Phenotypic Diversity Affects Metabolic Fitness and Host Interactions. [europepmc]
- Fungemia in Hospitalized Adult Patients with Hematological Malignancies: Epidemiology and Risk Factors. [europepmc]
- Absence of Clinically Meaningful Drug-Drug Interactions with Rezafungin: Outcome of Investigations. [europepmc]
- The impact of increasing non-albicans Candida trends on diagnostics in immunocompromised patients. [europepmc]
- Enhancing the Antifungal Efficacy of Fluconazole with a Diterpene: Abietic Acid as a Promising Adjuvant to Combat Antifungal Resistance in Candida spp. [europepmc]
- Population pharmacokinetic modeling and target attainment analyses of rezafungin for the treatment of candidemia and invasive candidiasis. [europepmc]
- Diagnosis and management of invasive fungal diseases in non-neutropenic ICU patients, with focus on candidiasis and aspergillosis: a comprehensive review. [europepmc]
- Epidemiology of Invasive Candidiasis. [europepmc]
- A Narrative Review of Invasive Candidiasis in the Intensive Care Unit. [europepmc]
Related